Heart Disease

CDK Inhibitor Effective For Cardiac Hypertrophy In Vitro And In Vivo

Published in Gene Therapy Weekly, September 20th, 2001

by N.R. Saltmarsh, staff medical writer - Delivery of the cyclin-dependent kinase (cdk) inhibitor p16(INK4a) by adenovirus vector has potential for treatment of cardiac hypertrophy, one of the serious complications of cardiovascular disease.

Current drug therapy is only partially successful at reducing cardiac hypertrophy, noted T. Nozato and colleagues working in Japan. They studied p16(INK4a) in vitro and in the rat model to see if it offered a better alternative.

"Adenovirus-mediated overexpression of p16(INK4a) completely inhibited cardiac myocyte hypertrophy induced by endothelin (ET)-1, as evaluated by [H-3]leucine incorporation into the cells...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-09-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry